Precision Assessment of Anti-NMDA Receptor Encephalitis: A Case Report on Integrating Clinical Course, Immunophenotyping, and Comprehensive Symptomatology in a Pediatric Patient With Adjunctive Hydrogen Therapy.
Lin SC, Lu JW, Lin TC, Sung YF, Ho YJ, Wang FM, Lui SW, Hsieh TY, Wang KY, Liu FC. · In Vivo. 2025;39:13858.
What kind of evidence is this?
Human
Case report
Other neurological conditions
Other forms
Indeterminate for molecular hydrogen.
Clinical and biomarker outcomes in a single patient.
Methods at a glance
One pediatric patient with anti-NMDA receptor encephalitis receiving intensive immunotherapy.
1 patient.
Follow-up over the treatment timeline reported in the article.
One oral hydrogen-generating capsule daily as adjunctive therapy.
Hydrogen generated after capsule ingestion; not Brown's gas.
Systemic hydrogen exposure was not directly measured.
Not applicable — oral capsule.
No oxygen was co-delivered.
No control; longitudinal clinical course.
Outcomes and reported result
Neurologic symptoms, clinical course and immune phenotyping.
The report describes clinical and immunologic changes after hydrogen was added to rituximab, intravenous immunoglobulin and other care.
The full case report, treatment timeline, clinical observations and immune measurements were checked.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Concurrent intensive treatment and natural recovery make causal attribution to hydrogen impossible.
This individual case only.
JBI Case Report Checklist — preliminary
Serious concerns
No comparator and major time-varying confounding from immunotherapy and supportive care.
Single selected case · Co-interventions were present · Follow-up described in the report · Several outcomes were clinician- or patient-reported · No prespecified analysis plan
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 39740868 · DOI: 10.21873/invivo.13858
Free full article in PubMed Central.
PubMed record and PubMed Central full text; extraction checked 9 August 2026.
2026-08-10